Company news
Firebrick Pharma Limited news in 2023
Firebrick Pharma Limited's news releases, calls and decks from 2023, newest first.
Firebrick Investor Update
November 14, 2023
Firebrick Receives $1.81m R&D Tax Incentive
October 30, 2023
September 2023 Quarterly Activity Report & Appendix 4C
October 26, 2023
Update on Nasodine Trial and Forward Plans
October 2, 2023
Phase 3 Common Cold Trial Results
September 13, 2023
Appendix 4E & Annual Report FY23
August 29, 2023
Response to ASX Price and Volume Query
August 28, 2023
Firebrick Phase 3 Trial Closes with 500 Subjects
August 8, 2023
Firebrick Covid-19 Trial Achieves Primary Endpoint
August 6, 2023
June 2023 Quarterly Activity Report & Appendix 4C
July 26, 2023
Nasodine Phase 3 Clinical Trial Surpasses 80% Recruitment
May 30, 2023
Firebrick Raises $1 million via Placement
April 30, 2023
March 2023 Quarterly Activity Report & Appendix 4C
April 19, 2023
Nasodine COVID-19 Trial Concludes Recruitment
April 3, 2023
Firebrick Pharmas Phase 3 Trial of Nasodine Resumes
March 20, 2023
FRE files EU Paediatric Investigation Plan for Nasodine
February 20, 2023
Appendix 4D & Half Yearly Report and Accounts
February 17, 2023
December 2022 Quarterly Activity Report & Appendix 4C
January 18, 2023
Decks in 2023
- Euroz Hartleys Healthcare Forum 2023
Conference · 20 slides · Feb 1, 2023